Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical Limited has announced the successful completion of phase III clinical trials for its innovative drug Culmerciclib, which has shown promise in treating hormone receptor-positive, HER2-negative advanced breast cancer. The new drug application for Culmerciclib has been accepted by China’s National Medical Products Administration, marking a significant step towards offering a new treatment option for breast cancer patients. Culmerciclib’s enhanced inhibitory effects on CDK2 and CDK4 may improve resistance issues found with current treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
